DE102016124171A1 - Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen - Google Patents

Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen Download PDF

Info

Publication number
DE102016124171A1
DE102016124171A1 DE102016124171.7A DE102016124171A DE102016124171A1 DE 102016124171 A1 DE102016124171 A1 DE 102016124171A1 DE 102016124171 A DE102016124171 A DE 102016124171A DE 102016124171 A1 DE102016124171 A1 DE 102016124171A1
Authority
DE
Germany
Prior art keywords
hpv16
antibodies
antigens
antibody
capsomeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102016124171.7A
Other languages
German (de)
English (en)
Inventor
Ralf Hilfrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abviris Deutschland De GmbH
Original Assignee
Abviris Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abviris Deutschland GmbH filed Critical Abviris Deutschland GmbH
Priority to DE102016124171.7A priority Critical patent/DE102016124171A1/de
Priority to BR112019011681-8A priority patent/BR112019011681A2/pt
Priority to LTEP17835602.8T priority patent/LT3384292T/lt
Priority to PL17835602T priority patent/PL3384292T3/pl
Priority to US16/090,159 priority patent/US10852303B2/en
Priority to EP17835602.8A priority patent/EP3384292B1/en
Priority to DK17835602.8T priority patent/DK3384292T3/da
Priority to HRP20211080TT priority patent/HRP20211080T1/hr
Priority to SM20210421T priority patent/SMT202100421T1/it
Priority to RU2019121882A priority patent/RU2757629C2/ru
Priority to CA3045729A priority patent/CA3045729A1/en
Priority to KR1020197020463A priority patent/KR102433541B1/ko
Priority to RS20210859A priority patent/RS62135B1/sr
Priority to SI201730846T priority patent/SI3384292T1/sl
Priority to HUE17835602A priority patent/HUE054969T2/hu
Priority to JP2019532928A priority patent/JP7329244B2/ja
Priority to PCT/EP2017/082506 priority patent/WO2018108957A1/en
Priority to ES17835602T priority patent/ES2880489T3/es
Priority to CN201780077269.1A priority patent/CN110073219B/zh
Priority to PT178356028T priority patent/PT3384292T/pt
Publication of DE102016124171A1 publication Critical patent/DE102016124171A1/de
Priority to ZA2018/04516A priority patent/ZA201804516B/en
Priority to US17/015,955 priority patent/US11506667B2/en
Priority to CY20211100609T priority patent/CY1124297T1/el
Priority to JP2022200001A priority patent/JP2023029377A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE102016124171.7A 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen Withdrawn DE102016124171A1 (de)

Priority Applications (24)

Application Number Priority Date Filing Date Title
DE102016124171.7A DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen
KR1020197020463A KR102433541B1 (ko) 2016-12-13 2017-12-13 Hpv 16 양성 암종의 치료 조절을 위한 혈청학적 검사
SI201730846T SI3384292T1 (sl) 2016-12-13 2017-12-13 Serološki test za kontrolo terapije karcinoma, pozitivnega na HPV16
PL17835602T PL3384292T3 (pl) 2016-12-13 2017-12-13 Test serologiczny do kontrolowania terapii raka HPV16-dodatniego
US16/090,159 US10852303B2 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of HPV16 positive carcinoma
EP17835602.8A EP3384292B1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma
DK17835602.8T DK3384292T3 (da) 2016-12-13 2017-12-13 Serologisk test til terapistyring af HPV16-positivt karcinom
HRP20211080TT HRP20211080T1 (hr) 2016-12-13 2017-12-13 Serološki test za terapijsku kontrolu hpv16 pozitivnog karcinoma
SM20210421T SMT202100421T1 (it) 2016-12-13 2017-12-13 Test sierologico per controllo di terapia di carcinoma hpv16-positivo
RU2019121882A RU2757629C2 (ru) 2016-12-13 2017-12-13 Серологический тест для терапевтического контроля впч16-положительной карциномы
LTEP17835602.8T LT3384292T (lt) 2016-12-13 2017-12-13 Serologinis testas, skirtas hpv16 atžvilgiu teigiamos karcinomos terapijos kontrolei
BR112019011681-8A BR112019011681A2 (pt) 2016-12-13 2017-12-13 teste sorológico para controle terapêutico de carcinoma hpv16 positivo
RS20210859A RS62135B1 (sr) 2016-12-13 2017-12-13 Serološki test za terapijsku kontrolu hpv16 pozitivnog karcinoma
JP2019532928A JP7329244B2 (ja) 2016-12-13 2017-12-13 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査
CA3045729A CA3045729A1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma
HUE17835602A HUE054969T2 (hu) 2016-12-13 2017-12-13 Szerológiai teszt HPV16-pozitív karcinóma terápiás kontrolljára
PCT/EP2017/082506 WO2018108957A1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma
ES17835602T ES2880489T3 (es) 2016-12-13 2017-12-13 Prueba serológica para el control de terapia de carcinoma VPH16 positivo
CN201780077269.1A CN110073219B (zh) 2016-12-13 2017-12-13 用于对hpv16阳性癌的治疗控制的血清学测试
PT178356028T PT3384292T (pt) 2016-12-13 2017-12-13 Teste sorológico para controlo terapêutico de carcinoma hpv16 positivo
ZA2018/04516A ZA201804516B (en) 2016-12-13 2018-07-06 Serologic test for therapy control of hpv16 positive carcinoma
US17/015,955 US11506667B2 (en) 2016-12-13 2020-09-09 Serologic test for therapy control of HPV16 positive carcinoma
CY20211100609T CY1124297T1 (el) 2016-12-13 2021-07-06 Ορολογικη εξεταση για τον ελεγχο της θεραπειας καρκινωματος θετικου σε hpv16
JP2022200001A JP2023029377A (ja) 2016-12-13 2022-12-15 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102016124171.7A DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen

Publications (1)

Publication Number Publication Date
DE102016124171A1 true DE102016124171A1 (de) 2018-06-14

Family

ID=61027644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102016124171.7A Withdrawn DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen

Country Status (22)

Country Link
US (2) US10852303B2 (https=)
EP (1) EP3384292B1 (https=)
JP (2) JP7329244B2 (https=)
KR (1) KR102433541B1 (https=)
CN (1) CN110073219B (https=)
BR (1) BR112019011681A2 (https=)
CA (1) CA3045729A1 (https=)
CY (1) CY1124297T1 (https=)
DE (1) DE102016124171A1 (https=)
DK (1) DK3384292T3 (https=)
ES (1) ES2880489T3 (https=)
HR (1) HRP20211080T1 (https=)
HU (1) HUE054969T2 (https=)
LT (1) LT3384292T (https=)
PL (1) PL3384292T3 (https=)
PT (1) PT3384292T (https=)
RS (1) RS62135B1 (https=)
RU (1) RU2757629C2 (https=)
SI (1) SI3384292T1 (https=)
SM (1) SMT202100421T1 (https=)
WO (1) WO2018108957A1 (https=)
ZA (1) ZA201804516B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102022127779A1 (de) 2022-10-20 2024-04-25 Ralf Hilfrich Serologischer Test zum Nachweis von Antikörpern gegen HPV und Testkit

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147961A1 (en) * 2002-04-30 2005-07-07 Esser Mark T. Human papillomavirus multiplexed assay

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) * 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
CN101245099A (zh) * 2007-02-14 2008-08-20 马润林 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
DE102010061028A1 (de) * 2010-12-03 2012-06-06 Ralf Hilfrich Schnelltest zum qualitativen und/oder quantitativen Bestimmen von Körperflüssigkeit enthaltenen Antikörpern gegen humane Papillomviren sowie Vorrichtung zum Durchführen des Schnelltests
DE102011053741A1 (de) * 2011-09-19 2013-03-21 Ralf Hilfrich Verfahren zum Überprüfen der Selbstheilung durch das Immunsystem eines mit humanen Papillomviren infizierten Menschen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147961A1 (en) * 2002-04-30 2005-07-07 Esser Mark T. Human papillomavirus multiplexed assay

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Af Geijerstam et al. beschreiben in Journal of Infectious Diseases, 177, 1998, 1710-1714
CHRISTENSEN, Neil D., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology, 1996, 223. Jg., Nr. 1, S. 174-184. *
Koslabova et al. stellten in International Journal of Cancer, 133, 2013, 1832-1839
Shah et al., Cancer Epidemiology, Biomarkers & Preventions, 6, 1997, 233-237
Volpers, C., P. Schirmacher, R. E. Streeck, and M. Sapp. 1994

Also Published As

Publication number Publication date
SI3384292T1 (sl) 2021-08-31
RU2757629C2 (ru) 2021-10-19
EP3384292B1 (en) 2021-04-21
KR102433541B1 (ko) 2022-08-18
LT3384292T (lt) 2021-07-26
KR20190097155A (ko) 2019-08-20
BR112019011681A2 (pt) 2019-10-15
ZA201804516B (en) 2019-04-24
RS62135B1 (sr) 2021-08-31
CY1124297T1 (el) 2022-07-22
RU2019121882A3 (https=) 2021-04-09
RU2019121882A (ru) 2021-01-15
SMT202100421T1 (it) 2021-09-14
JP2020501162A (ja) 2020-01-16
JP7329244B2 (ja) 2023-08-18
US20190113516A1 (en) 2019-04-18
US11506667B2 (en) 2022-11-22
ES2880489T3 (es) 2021-11-24
CN110073219B (zh) 2023-09-05
CN110073219A (zh) 2019-07-30
US20200408768A1 (en) 2020-12-31
EP3384292A1 (en) 2018-10-10
JP2023029377A (ja) 2023-03-03
PL3384292T3 (pl) 2021-10-25
DK3384292T3 (da) 2021-06-28
WO2018108957A1 (en) 2018-06-21
HRP20211080T1 (hr) 2021-10-01
HUE054969T2 (hu) 2021-10-28
CA3045729A1 (en) 2018-06-21
US10852303B2 (en) 2020-12-01
PT3384292T (pt) 2021-07-22

Similar Documents

Publication Publication Date Title
DE69333859T2 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus hüllproteine
DE69434383T2 (de) Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE60132770T2 (de) Chimäre humane papillomavirus (hpv) l1 moleküle und deren verwendungen
DE69104380T2 (de) Vom genom des papillomavirus-hpv-39 abgeleitete dns-sequenzen, deren anwendung in der in vitro-diagnose und zur herstellung einer immunogenenzusammensetzung.
US5968522A (en) Immunogenic compositions and antibodies directed against human papillomavirus type 49 (HPV 49), type 50 (HPV 50), type 54 (HPV 54), and type 55 (HPV 55).
DE68912342T2 (de) Verfahren zum nachweis des menschlichen papillomavirus (hpv) für diagnosezwecke.
Heim et al. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups
Xiao et al. Observations on the expression of human papillomavirus major capsid protein in HeLa cells
Heino et al. Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma
Le Cann et al. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus
Hagensee et al. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies
DE102016124171A1 (de) Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen
DE19526386C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE69933891T2 (de) Behandlung von papillomavirus-infektionen
EP0707652A1 (de) Für ein peptid eines papillomvirus-hauptcapsid-proteins codierende dna und dessen verwendungen
DE69924007T2 (de) Neutralsierungs-assay, das humane papillomavirus-ähnliche partikel verwendet
DE69330966T2 (de) DNA-Sequenzen des Epstein-Barr Virus kodierend für ein diagnostisch relevantes Virus-Hüllprotein, durch PCR erhaltene Expressionsklone und Verwendung dieses rekombinanten Antigens in diagnostischen Tests
DE19735118C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
EP0972047A2 (de) Papillomviren-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
DE4332596A1 (de) Monoklonale Antikörper
DE9106105U1 (de) Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
EP1146881B1 (de) Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
Müller et al. of Human Papillomavirus Type 16
DE19943787A1 (de) Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs
DE19943786A1 (de) Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R081 Change of applicant/patentee

Owner name: ABVIRIS DEUTSCHLAND GMBH, DE

Free format text: FORMER OWNER: ABVIRIS DEUTSCHLAND GMBH, 22949 AMMERSBEK, DE

R082 Change of representative

Representative=s name: EISENFUEHR SPEISER PATENTANWAELTE RECHTSANWAEL, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee